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West Nile virus has spread rapidly across the United States, and there is currently no approved human
vaccine or therapy to prevent or treat disease. Passive immunization with antibodies against the envelope
protein represents a promising means to provide short-term prophylaxis and treatment for West Nile virus
infection. In this study, we identified a panel of 11 unique human single-chain variable region antibody
fragments (scFvs) that bind the envelope protein of West Nile virus. Selected scFvs were converted to Fc fusion
proteins (scFv-Fcs) and were tested in mice for their ability to prevent lethal West Nile virus infection. Five of
these scFv-Fcs, 11, 15, 71, 85, and 95, protected 100% of mice from death when given prior to infection with
virus. Two of them, 11 and 15, protected 80% of mice when given at days 1 and 4 after infection. In addition,
four of the scFv-Fcs cross-neutralized dengue virus, serotype 2. Binding assays using yeast surface display
demonstrated that all of our scFvs bind to sites within domains I and II of West Nile virus envelope protein.
These recombinant human scFvs are potential candidates for immunoprophylaxis and therapy of flavivirus
infections.
West Nile virus (WNV) is a mosquito-borne Flavivirus that
causes febrile illness and neurological disease in humans,
horses, and birds (18). Endemic to Africa, the Middle East,
Europe, and Asia, WNV was first detected in the United States
in 1999 (6). Since its introduction into North America, WNV
has spread throughout the lower 48 states, as well as into
Canada, Mexico, and the Caribbean (10). In humans, WNV
infection can develop into meningitis or encephalitis and may
lead to death, particularly among the elderly and immunocom-
promised (6).
As WNV disseminates across the country, the need for ef-
fective vaccines and therapies continues to grow. Currently
there is no WNV vaccine approved for human use, and the
only treatments are supportive. In vitro studies have found
ribavirin and alpha2b interferon to be effective against the
virus (3, 14, 31), and several human case studies have found
that alpha interferon may improve the clinical outcome of
WNV infection (15, 25). Antibodies, including both monoclo-
nal antibodies (MAbs) and polyclonal immune sera, represent
another potential direction for influencing disease outcome.
Several human case reports have suggested that the adminis-
tration of immune pooled intravenous immunoglobulin (Ig)
may aid in the recovery from WNV infection (1, 11, 12, 26);
however, there have been no controlled clinical trials demon-
strating the efficacy of intravenous Ig as a treatment for WNV.
In a murine model of WNV, antibody therapy has been
shown to be effective both as prophylaxis and as treatment for
infection. Mice administered human anti-WNV gamma glob-
ulin prior to infection were protected from disease, while those
given gamma globulin after infection had spread to the central
nervous system had an improved clinical outcome (5, 7). Sim-
ilarly, hamsters administered immunoglobulin 24 h prior to
infection were completely protected from infection (28). The
WNV envelope (E) glycoprotein is a likely candidate protein
to target using passive immunization (23, 30), and monoclonal
antibodies produced against the E protein have been found to
protect mice from lethal infection (19). Augmenting the level
of antibodies against the WNV E protein may prove to be an
important treatment strategy for infection, particularly for el-
derly and immunocompromised patients with immune system
deficiencies.
Several MAbs provide cross-protection in animal models
against related flavivirus infections (8, 23). The development of
cross-protective antibodies is of particular interest because it
would be possible to prevent and/or treat several different
infections with the same therapeutic antibody preparation.
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Because many of the flaviviruses are recognized by cross-reac-
tive antibodies, a cross-protective therapy could be used in the
absence of virus-specific diagnostics and will reduce the time
before treatment can be initiated.
The use of nonhuman antibodies in patients has safety con-
siderations, including cross-species sensitization and potential
contamination with blood-borne pathogens. Many of these
problems can be overcome by the use of specific humanized
antibodies. Recombinant human antibodies created in an in
vitro system, such as the phage display system used in this
study, provide many advantages over conventional antibody
development techniques. These antibodies can be quickly and
easily developed at a high titer, are free of blood-borne patho-
gens, and can be produced without the need for immunization.
In addition, human antibodies can be administered without
complications of serum sickness or other immune responses to
the presence of nonhuman antigens (24).
Although there is a large body of data on murine flavivirus
MAbs, there have been few flavivirus MAbs identified from
humans or other primates (9). More information regarding
human MAbs is clearly needed to develop optimal prophylaxis
and treatment strategies for human disease. In this study, we
have developed and evaluated the efficacy of recombinant hu-
man single-chain variable fragments (scFv) fused to an IgG1
Fc domain and a polyclonal E protein antiserum as both pro-
phylaxis and treatment for lethal WNV infection. We have also
evaluated the ability of these antibodies to neutralize related
flaviviruses. This study is the first study to characterize human
antibodies against WNV and is the first study to use a phage
display screen to identify human antibodies against WNV.
MATERIALS AND METHODS
Screening of phage libraries. scFvs against the WNV E protein were identified
using a phage display screen. Two human, nonimmune phage display libraries
were screened; both were created from the B cells of normal, non-WNV-immune
humans and contain between 12 and 15 billion unique phage displayed in the
phagemid vector pFarber as fusion proteins with phage coat protein III (27;
http://research.dfci.harvard.edu/nfcr-ctae/research/mehta.php). Maxisorp immu-
notubes (Nalge Nunc International) were coated overnight with recombinant
WNV E protein antigen (rWNV-E) that was expressed in Drosophila melano-
gaster S2 cells and highly purified (17, 32) at a concentration of 15 g/ml in
phosphate-buffered saline (PBS), pH 7.4. Phage (5  1012) were added to the
tubes and allowed to bind for 2 h at room temperature. Nonspecifically absorbed
phages were removed by extensive washing (15 times with PBS–0.05% Tween 20,
15 times with PBS), and bound phage were eluted in 100 mM triethylamine.
Eluted phage were allowed to infect Escherichia coli TG1 cells, and pooled phage
were rescued by VCS M13 helper phage and concentrated by polyethylene
glycol-NaCl precipitation (27). Four rounds of selection were performed. Fol-
lowing the second, third, and fourth rounds of selection, individual TG1 colonies
were screened by enzyme-linked immunosorbent assay (ELISA).
For ELISA screening, 96-well microtiter plates were coated overnight with
rWNV-E (10 g/ml) in PBS, pH 7.4. Plates were blocked with PBS–2% milk for
1 h. After extensive washing with PBS-Tween 20, plates were incubated with
anti-M13–horseradish peroxidase (HRP) conjugate (Amersham) to detect the
M13 tag on the scFvs, developed with Sure Blue Microwell peroxidase (KPL),
and stopped after 10 min with tetramethylbenzidine stop solution (KPL), and the
optical density at 450 nm (OD450) was measured. Phage that bound to rWNV-E
with an OD450 of 1.0 were scored as positive. Phage clones that bound to
rWNV-E were sequenced, and their corresponding amino acid sequences were
aligned.
Expression and purification of scFvs and scFv-Fc fusion proteins. Antibody
genes of rWNV-E-specific scFvs were excised from the phagemid vector by
NotI-NcoI digestion and ligated into the prokaryotic expression vector pSyn (4),
which adds C-terminal c-myc and His6 tags. E. coli XL-1 Blue cells were trans-
formed with the plasmids, individual colonies were screened by restriction di-
gestion, and the insert DNA sequences were verified. For scFv expression,
bacteria were grown in 2 YT (tryptone-yeast extract) medium containing 0.1%
glucose and 100 g/ml ampicillin and were induced overnight with 1 mM iso-
propyl--D-thiogalactopyranoside at 30°C. Bacterial cultures were pelleted and
resuspended in PBS containing Complete Protease Inhibitor Cocktail tablets
(Roche), and the cultures were sonicated for 2 min. The sonicate was centrifuged
to remove insoluble debris, the protein was precipitated from the supernatant
with 4.1 M ammonium sulfate, and the precipitated protein was purified on a
chelating Sepharose (Amersham) column. Purified scFvs were dialyzed overnight
against PBS, concentrated, and stored at 70°C.
Purified scFvs were tested for their binding activity against rWNV-E by
ELISA. Ninety-six-well microtiter plates were coated overnight with rWNV-E
(1 g/ml in PBS). Plates were blocked with PBS–2% milk, followed by incubation
with 10-fold dilutions of the scFvs for 1 h at room temperature. Monoclonal
anti-His-HRP (1:4,000; Invitrogen Corporation, Carlsbad, CA) was added for
1 h, and the plates were developed and read as described above.
For production of scFv-Fc fusion proteins, antibody genes were excised from
the phagemid vector by NotI-SfiI digestion and cloned into the human IgG1
expression vector pcDNA 3.1 Hinge. scFv-Fc fusion proteins were expressed in
293T cells by transient calcium phosphate transfection and purified by protein
A-Sepharose (Amersham) affinity chromatography. scFv-Fc fusions were
screened for binding activity against rWNV-E by ELISA as described above for
purified scFvs using antihuman IgG-HRP (Sigma) as a secondary antibody.
Serum and rabbit IgG preparation. A New Zealand White rabbit was immu-
nized with 50 g of rWNV-E in complete Freund’s adjuvant and boosted twice
with the same antigen in incomplete Freund’s adjuvant at 3-week intervals, and
the serum was collected. The IgG fraction was purified from the whole rabbit
sera by protein G affinity chromatography (Amersham). Nonimmune rabbit
serum was obtained from animals with no history of flavivirus exposure and with
no reactivity to the E protein as measured by ELISA and Western blotting.
Normal, nonimmune human IgG1 was obtained from Sigma.
The F(ab)2 fraction was prepared from the purified anti-rWNV-E IgG frac-
tion by digestion with immobilized pepsin using the Immunopure F(ab)2 prep-
aration kit (Pierce). Intact IgG and Fc fragments were removed from the digests
by protein A column chromatography, and the F(ab)2 fraction was further
purified by Sephacryl S-100 column chromatography in PBS. Protein concentra-
tion was determined by bicinchoninic acid protein assays (Pierce).
PRNT assay. For the plaque reduction neutralization (PRNT) assay, Vero
cells (ATCC CCL-81) were seeded in six-well plates at a density of 2  105
cells/ml 24 h before infection. For WNV (strain 2741, a lineage I isolate) (2, 20)
and St. Louis encephalitis virus (SLEV; strain Parton P-3) neutralization, cells
were maintained in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal calf serum (FCS) and 100 g/ml penicillin-streptomycin at 37°C in 5%
CO2. For dengue virus serotype 2 (DENV-2; strain New Guinea C) neutraliza-
tion, cells were maintained in Dulbecco’s modified Eagle’s medium–F-12 sup-
plemented with 10% FCS, 100 g/ml penicillin-streptomycin, and 100 g/ml
amphotericin B (Fungizone) at 37°C in 5% CO2.
Serial dilutions of IgG, scFvs, or scFv-Fcs were mixed with 100 PFU virus and
incubated for 1 h at 37°C in 5% CO2. The virus-antibody mixture was added to
the cell monolayers and incubated for another hour. Cells were overlaid with 3
to 4 ml of 1% agarose in cell culture medium, and after 4 days a second overlay
of 2.5 ml 1% agarose-medium containing 0.01% neutral red was added to
visualize plaques. The neutralization assay for DENV-2 was conducted as de-
scribed above, but cells were incubated for 6 days before the second overlay.
Affinity measurements by Biacore. The binding kinetics and affinity of the
scFvs for rWNV-E were measured by surface plasmon resonance (Biacore 3000,
Uppsala, Sweden). scFvs (30 to 50 g/ml) were covalently immobilized to a
nitrilotriacetic acid (NTA) sensor chip (Biacore) via their histidine tag. The
running buffer used contained 0.01 M HEPES (pH 7.4) with 0.15 M NaCl2, 50
M EDTA, and 0.005% Surfactant P20 (Biacore). The NTA surface was acti-
vated with 500 M NiCl2 in running buffer. All experiments were run at a flow
rate of 20 l/minute in HBS-EP buffer (Biacore). The chip surface was regen-
erated with 0.01 M HEPES with 0.15 M NaCl, 0.35 M EDTA, and 0.005%
Surfactant P20, pH 8.3. The binding kinetic parameters were measured by vary-
ing the molar concentration (0.704 to 440 nM) of rWNV-E and analyzed using
BIA-EVALUATION software (Biacore).
To measure the binding affinity of the scFv-Fcs to rWNV-E, scFv-Fcs (30
g/ml) were first captured using goat anti-human IgG (30 g/ml in 10 mM
sodium acetate, pH 5.0; Bethyl Laboratories, Montgomery, TX) that was co-
valently coupled to a CM4 sensor chip (Biacore) using an amine coupling kit
(Biacore). Assays with the scFv-Fcs were run at a flow rate of 20 l/minute in
HBS-EP buffer (Biacore), and the chip surface was regenerated with 10 mM
glycine, pH 1.8. The binding kinetics were measured and analyzed as above.
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Mouse passive immunization and viral challenge. Groups of 5 to 10 female
C57BL/6 mice (Jackson Laboratories) between 4 and 6 weeks of age were used
in all experiments. Mice were infected with 102 to 103 PFU WNV intraperito-
neally. In experiments with rabbit antibodies, mice were injected intraperitone-
ally with the indicated doses of serum or IgG at times ranging from 1 day prior
to 5 days post-WNV infection. Human IgG1, scFvs, and scFv-Fc constructs were
administered subcutaneously either 24 h before or up to 96 h after virus inocu-
lation. Survival was recorded daily until no further deaths had occurred for at
least 7 days or for 21 days after infection, whichever came last. All animal
experiments were conducted in accordance with the Yale University Animal
Care and Use Committee regulations.
Domain mapping. The E protein ectodomain, DIII, and DI/DII were cloned
into a yeast display vector, pYD1 (Invitrogen), as previously described (19). This
expression vector displays proteins of interest as a fusion protein with the AGA2
gene of Saccharomyces cerevisiae. Briefly, the clones were then transformed into
S. cerevisiae strain EBY 100. The transformed yeast cells were grown on minimal
dextrose plates containing leucine. Single colonies were grown overnight in yeast
nitrogen base-Casamino Acids medium containing 2% glucose, and display of
the fusion protein was induced by the addition of 2% galactose at log phase. The
expression of the fusion protein was monitored for 12 to 48 h postinduction to
determine the optimal induction time for maximum display. Protein display was
confirmed by staining with anti-Xpress antibody (Invitrogen).
Yeast cells expressing pYD1, the WNV ectodomain, WNV DIII, or WNV
DI/DII were plated in 96-well plates and incubated for 30 min on ice with
scFv-Fcs (1 g/ml) conjugated to Alexa Fluor 647 (Invitrogen/Molecular Probes)
at a 1:500 dilution. scFv-Fc conjugates were prepared according to the manu-
facturer’s directions. Cells were washed three times with PBS–1% bovine serum
albumin, and the cells were fixed in 1% paraformaldehyde and counted on a
FACsCalibur (Becton Dickinson). Data were analyzed with Cell Quest software.
Alternatively, unconjugated antibodies were incubated with yeast at a concen-
tration of 50 g/ml for 30 min on ice, followed by incubation with goat anti-
human IgG–Alexa Fluor 647 (Invitrogen/Molecular Probes) at a concentration
of 1:500 in 1 mg/ml bovine serum albumin in PBS for an additional 30 min. Cells
were washed and fixed as described above.
RESULTS
Passive immunization with rabbit anti-rWNV-E IgG. Stud-
ies were first performed with a well-characterized rabbit poly-
clonal rabbit anti-rWNV-E antibody to establish the dose and
timing of antibody therapy in the murine model (30). As ex-
pected, passive transfer of rabbit anti-rWNV-E serum or the
IgG fraction purified from the rabbit antiserum completely
protected C57BL/6 mice from lethal infection with WNV when
given prior to infection. In addition, a single dose of rabbit
anti-rWNV-E IgG was active therapeutically up to 4 days post-
viral challenge (Fig. 1). Antibodies given after day 5 were not
able to rescue infected mice, and mice succumbed to infection
(data not shown). Even though antibodies administered at days
1 and 3 after infection did not protect 100% of mice, there was
a significant increase in the average survival time among mice
administered antibody at day 1, 1, or 3 but not for mice
administered antibody at day 4 or 5. Mice given antibody at day
4 or 5 (14.3  7.2 or 11.0  3.7 days, respectively) did not differ
significantly in their average survival time from mice given
virus only (7.3  0.8 days).
Although intact antibody molecules have the advantage of
Fc-mediated functions, in some cases, the use of intact anti-
body molecules for immunoprophylaxis and therapy is limited.
Intact antibody molecules are normally unable to cross the
blood-brain barrier, and the Fc region is the source of cross-
species neutralizing antibodies and potentially causes Fc-me-
diated antibody-dependent enhancement (ADE) of infection.
To circumvent these complications, we also tested the efficacy
of F(ab)2 antibody fragments in in vivo protection assays.
F(ab)2 fragments provided only partial protection from a le-
thal dose of WNV (Fig. 2), suggesting that Fc-mediated effec-
tor functions are important for optimal protection against oth-
erwise lethal WNV infection.
Identification of anti-rWNV-E scFvs. scFv human monoclo-
nal antibodies against the E protein were identified by phage
display screening. Purified rWNV-E was used as an antigen to
select antibodies from two nonimmune human scFv libraries.
After four rounds of selection, a total of 384 clones were
screened by ELISA for binding. Eleven unique anti-rWNV-E
scFvs were then identified by DNA sequence analysis.
Amino acid sequences predicted by sequence analysis of the
VH and VL of the 11 scFv genes are shown in Fig. 3. All of the
VH sequences were in the VH1 gene family; VL sequences were
in the VL1, VL2, VL3, and VL8 gene families. scFvs 10, 11, 15,
71, 73, 84, 85, and 95 had identical or nearly identical VH
sequences, while scFvs 69, 79, and 94 had distinct VH se-
quences, particularly in CDR2 and CDR3, the primary do-
mains involved in antigen binding. VL sequences were distinct
for all 11 scFvs.
The 11 scFvs tagged with c-myc and His6 epitopes were
expressed in E. coli and purified by immobilized metal affinity
chromatography. scFv binding activity to rWNV-E was exam-
ined by both ELISA and Western blotting (Fig. 4). By ELISA,
FIG. 1. Survival of mice passively immunized with rabbit anti-
rWNV-E IgG. Groups of 10 mice were injected with a single dose of
500 g of rabbit anti-rWNV-E IgG at the indicated times before or
after infection with 100 PFU WNV. Data are representative of two
experiments with similar results.
FIG. 2. Survival of mice passively immunized with rabbit anti-
rWNV-E F(ab)2. Groups of 10 mice were injected with a single dose
of 500 g of anti-rWNV-E F(ab)2 before or after intraperitoneal
infection with 100 PFU WNV. The number of mice surviving was
recorded daily. Data are representative of two experiments with sim-
ilar results.
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8 of the 11 scFvs bound with high affinity to rWNV-E, while
scFvs 71, 84, and 94 bound less avidly to rWNV-E (Fig. 4a). By
Western blotting, we observed maximal binding to rWNV-E
under nonreducing conditions. When rWNV-E was reduced by
-mercaptoethanol, only weak binding was observed. The com-
plete epitopes recognized by the scFvs are likely conformation
dependent and are unavailable for binding under reduced con-
ditions (Fig. 4b). Secondary protein structure and conforma-
tional epitopes are thus critical for binding by the scFvs. When
the scFvs were modified to include an Fc domain, the ELISA
and Western blot binding profiles were similar (data not
shown). Additionally, the scFvs recognized native E protein in
Western blotting and immunofluorescence.
Affinity for rWNV-E. Binding kinetic rates (Kon and Koff) and
affinities of the scFvs and selected scFv-Fcs for rWNV-E were
measured by surface plasmon resonance (Table 1). The scFvs
ranged 20-fold in their affinity for the E protein, with the
highest binders displaying nanomolar affinities for the E pro-
tein. In comparison to their original scFv, the Kd of the scFv-
Fcs for rWNV-E was increased by approximately 2 orders of
magnitude. This is likely a result of the increased avidity of the
bivalent scFv-Fc for the E protein.
Neutralization of WNV, SLEV, and DENV-2. The rapid
blood clearance time of monovalent scFvs and their small size
may be a limiting factor for the use of these molecules in
passive immunotherapy (27). Bivalent molecules containing
the Fc region are often more effective at both virus neutral-
ization and stimulation of Fc-mediated effector functions and
have an increased serum half-life in vivo (21). To increase
these functions, selected scFvs were converted to scFv-Fc fu-
sions. The Fc expression vector used in these experiments,
pcDNA 3.1 Hinge, contains the hinge, CH2, and CH3 domains
of human IgG1 but lacks CH1.
Seven scFv-Fcs were assessed for neutralization of WNV in
FIG. 3. Amino acid sequences of anti-rWNV-E scFvs. Shown are the framework regions 1 to 4 (FW1 to FW4) and complementarity-
determining regions 1 to 3 (CDR1 to CDR3) for VH and VL, as well as VH and VL gene family designations. The consensus amino acid sequence,
encoded by more than 50% of the genes at a given position, is shown at the top. Dots in the consensus sequence are shown where 	50% of the
genes encode the same amino acid, and dots in each sequence represent the same amino acid as the consensus. Gaps are represented by dashes.
FIG. 4. Binding of scFvs to rWNV-E. (a) Binding of scFvs to rWNV-E as measured by ELISA. ELISA plates were coated with rWNV-E (100
ng/well) overnight and incubated with serial dilutions of antibodies. Anti-His-HRP (1:4,000) was used as a secondary antibody, and the plates were
developed and read at 450 nm (OD450). (b) rWNV-E (10 g/gel) was run on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel
under reducing (in the presence of 2-mercaptoethanol) or nonreducing conditions and blotted to nitrocellulose. Blots were incubated with scFvs
(1 g/ml), and binding was detected by incubation with anti-His-HRP (1:4,000). Lane Ab refers to control for background anti-His-HRP antibody
binding to rWNV-E.
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vitro using a standard Vero cell plaque assay. All of the seven
scFv-Fcs tested neutralized WNV plaque formation by greater
than 80%, at minimum concentrations ranging from 1.25 to
12.5 g/ml (Table 2). Consistent with its lower affinity for
rWNV-E, higher 84 scFv-Fc concentrations were required to
reduce plaque formation. Neutralization by scFvs was 10- to
20-fold less effective than by corresponding scFv-Fc proteins
(data not shown).
We next assessed the scFv-Fcs for their ability to neutralize
plaque formation by related flaviviruses. Several of the scFv-
Fcs were tested in a neutralization assay with DENV-2, and
one of the scFv-Fcs, scFv-Fc 79, was also tested for neutraliza-
tion of SLEV. All of the scFv-Fcs tested (scFv-Fcs 11, 15, 79,
and 95) resulted in greater than 80% neutralization of
DENV-2 at a concentration of 6.25 g/ml (Table 2). DENV-2
was not neutralized by the negative control antibody E53 or
anti-OspB specific to the WNV E protein or Borrelia burdorferi
OspB protein, respectively (not shown). scFv-Fc 79 also effec-
tively neutralized SLEV, with 5 g/ml resulting in 80%
plaque neutralization (PRNT80) by PRNT assay.
In vivo protection by scFv and scFv-Fcs. We next tested the
ability of the scFvs and the scFv-Fc fusion proteins to protect
mice from a lethal dose of WNV. A mixture of the scFvs (all
except 10) provided partial protection against lethal WNV
infection (Fig. 5a). Additionally, administration of 100 g of a
single scFv, 79, either 1 day before or 1 day after infection,
provided only partial protection against viral challenge (Fig.
5b). To confirm the critical role of the Fc region in protection
and to show that the bivalency of the scFv-Fc antibodies is not
sufficient for protection, mice were immunized with bivalent
F(ab)2 fragments derived from scFv-Fc 79. scFv-Fc 79 F(ab)2
was not protective in mice (data not shown), which is consis-
tent with our previous studies showing that rabbit F(ab)2 frag-
ments were only partially protective (Fig. 2).
As expected from their high in vitro affinity for rWNV-E and
the in vivo data with rabbit polyclonal anti-rWNV-E IgG, the
scFv-Fcs were both protective and therapeutically active. Ad-
ministration of 100 g of any of the scFv-Fcs 1 day prior to
infection with a lethal dose of WNV significantly increased
survival (Fig. 6a). ScFv-Fcs 11, 15, 73, 85 (not shown), and 95
protected 100% of mice challenged, scFv-Fc 79 provided 90%
protection, scFv-Fcs 71 and 94 (not shown) provided 80%
protection, and scFv-Fc 84 provided 60% protection. The pro-
tective capacity of these antibodies correlated with their bind-
ing to rWNV-E in ELISA and Western blots (Fig. 4).
We next examined the therapeutic activity of several of the
scFv-Fcs. Both scFv-Fcs 11 and 15 were therapeutically active,
with 80% of infected mice surviving when given two injections
consisting of 100 g of antibody at days 1 and 4 after infection
(Fig. 6b). Further experiments showed that scFv-Fc 11 was
more effective therapeutically than was scFv-Fc 15, with com-
plete protection against a lethal challenge dose up to 3 days
after infection by scFv-Fc 11. A dose of 250 g of scFv-Fc 11
protected 100% of mice when given 1 day after infection, and
a dose of 500 g protected 100% of mice at day 3. Mice given
500 g of scFv-Fc 11 at day 5 were partially protected from
death, and 60% of the mice survived infection. Naı̈ve mice had
100% mortality. A combination of antibodies 11 and 15 did not
improve survival. In all WNV challenge experiments, mice
administered antibodies showed no evidence of lasting mor-
bidity at greater than 21 days postinfection, as evidenced by
visual inspection for hind limb paralysis and daily weight mea-
surements.
Domain binding assay: scFv-Fcs bind to DI/DII. To deter-
mine which region of the WNV E protein is recognized by our
panel of scFv-Fc antibodies, we used a yeast display system to
express truncated WNV E proteins. Using this display method,
we evaluated binding of the scFv-Fcs to either DI/DII or DIII
of the WNV E protein. The control anti-WNV E MAbs E24
and E53 mapped to DIII and DI/DII, respectively, as shown
previously (19). All of the scFvs in this study bound to the
WNV E ectodomain. Interestingly, all of the scFVs in this
study mapped to DI/DII, and none mapped to DIII. (Fig. 7).
DISCUSSION
In the absence of a WNV vaccine for humans, passive im-
munization represents an important alternative strategy to pre-
vent and treat WNV infections. In this study, we evaluated the
protective and therapeutic capacity of human single-chain vari-
able fragments obtained by screening two antibody phage dis-
play libraries against recombinant WNV E protein.
We found that passive administration of polyclonal rabbit
antibodies against the E protein completely protected mice
from lethal WNV infection. Previous studies have similarly
protected mice from a lethal dose of WNV up to 5 days post-
viral challenge; however, 100% survival was not recorded (7).




1 s1) Koff (s1) Ka (M1) Kd (M)
scFv
10 5.61  105 2.12  102 2.64  107 3.78  108
11 3.26  105 1.61  103 2.03  108 4.92  109
15 1.33  105 1.28  103 1.04  108 9.65  109
69 2.13  105 1.26  103 1.69  107 5.92  108
71 9.39  104 2.58  103 3.64  107 2.75  108
73 5.17  105 2.25  103 2.30  108 4.35  109
79 1.25  105 6.70  104 1.87  108 5.35  109
84 1.81  105 6.85  103 2.65  107 3.78  108
85 5.01  106 6.73  103 7.45  108 1.34  109
95 2.35  105 7.15  104 3.29  108 3.04  109
scFv-Fc
79 2.62  104 3.58  107 7.34  1010 1.36  1011
95 3.20  105 1.09  105 2.94  1010 3.40  1011
TABLE 2. PRNT titers against WNV and DENV-2
scFv-Fc









a ND, not done.
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Because virus infection of the brain occurs between days 3 and
4 postinfection, antibody continues to provide at least partial
protection even after central nervous system infection has be-
gun. This is significant as the timing of infection in humans is
likely to be less clearly established than in an animal model and
patients may present to their clinician after WNV has crossed
the blood-brain barrier. Therefore, for an antibody to be ef-
fective as a therapeutic, it will ideally be effective even late in
the course of infection.
Using a phage display screen, we identified a panel of 11
scFvs that bound the recombinant WNV E protein. Selected
scFvs were converted into bivalent molecules with an IgG1 Fc
region to increase their in vivo protective capacity. Fc-medi-
ated activities are clearly important for efficacy of the antibody
molecules, as survival of mice passively immunized with the Fc
fusion proteins was increased, in some cases, to 100%. Simi-
larly, when the Fc region was removed from polyclonal rabbit
anti-E IgG, the F(ab)2 fraction was only partially protective.
Two of the scFv-Fc fusion proteins, 11 and 15, were found to
be therapeutically active against otherwise lethal WNV infec-
tion. Although some previous studies identified anti-WNV an-
tibodies that are protective in the absence of strong virus neu-
tralization (23), we found a correlation between binding to the
WNV E protein, virus neutralization, and in vivo protection.
The scFv-Fc fusion proteins have increased therapeutic and
protective capacity as compared to their cognate scFvs. A biva-
lent molecule and/or addition of the Fc region is typically
required for effective neutralization and in vivo efficacy by
scFvs (16, 22). The small size (26 kDa) of the monovalent scFvs
results in their rapid clearance, with a half-life as short as only
3.5 h (13), and is a limiting factor for their use in passive
immunization. In contrast, the half-life of the scFv-Fc fusion
proteins in vivo has been found to be increased to as long as 3
days (21). The comparatively short half-life of the scFvs may
partially explain why the pooled scFvs were only partially pro-
tective against WNV infection. Additionally, it is likely that
Fc-mediated activities in vivo contribute to the therapeutic
efficacy of the Fc fusion proteins against otherwise lethal WNV
infection (19).
Because many flaviviruses cocirculate in nature, an antibody
FIG. 5. Survival of mice passively immunized with scFvs. (a) Groups of five mice were injected intraperitoneally with a mixture of 10 scFvs (100
g each) 1 day prior to intraperitoneal inoculation with 100 PFU WNV. The number of mice surviving was recorded daily. Data are representative
of two separate experiments with similar results. (b) Groups of five mice were injected subcutaneously with 100 g of 79 scFv 79 either 1 day before
or 1 day after intraperitoneal inoculation with 100 PFU WNV. The number of mice surviving was recorded daily. Rabbit anti-rWNV-E (100 l)
was given 1 day before infection. Data are representative of two separate experiments with similar results.
FIG. 6. Survival of mice passively immunized with scFvs-Fcs. (a) Groups of 5 to 10 mice were injected subcutaneously with 100 g of scFv-Fcs
1 day prior to intraperitoneal inoculation with 100 PFU WNV. The number of mice surviving was recorded daily. One hundred percent of mice
treated with scFv-Fcs 11, 15, 73, and 95 survived. (b) Groups of 5 to 10 mice were injected subcutaneously with 100 g of scFv-Fcs 1 and 4 days
after intraperitoneal inoculation with 100 PFU WNV. The number of mice surviving was recorded daily. Eighty percent of mice treated with
scFv-Fc 11 or 15 survived, and 60% of mice treated with scFv-Fc 71 or 73 survived.
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that will protect against multiple viruses will have the highest
utility as both a short-term prophylaxis and a treatment. All
four of the scFv-Fcs tested provided in vitro protection against
DENV-2. Only scFv-Fc 79 was tested in a neutralization assay
with SLEV, and it effectively neutralized this related flavivirus.
While the in vivo activity of these scFv-Fcs against flaviviruses
other than WNV is not yet known, our in vitro data predict the
possibility of effective cross-protection. Although there are
theoretical concerns about the potential for ADE (29), we did
not find any evidence of immune enhancement in cultivated
human macrophages in vitro at saturating concentrations of
antibody (L. H. Gould, unpublished data). Similarly, none of
the antibodies enhanced infection in our WNV challenge as-
says. These results are consistent with those of other studies of
antibodies and WNV infection (7), and the significance of
ADE in vivo remains uncertain.
All of the scFv-Fcs characterized in this article positively
influenced the outcome of an otherwise lethal WNV infection;
however, there were distinct differences in the ability of these
antibodies to protect mice, both before and after infection. As
shown by the therapeutic experiments with scFv-Fc 11, an
increased dose of antibody is needed to effectively treat mice
later in the course of infection. The dose used in our experi-
ments may be suboptimal for some of the antibodies. Further
work is required to establish the most appropriate dosing and
timing regimens. Future investigations, guided in part by de-
tailed epitope mapping data, should also examine the potential
for increased protection with combinations of two or more
antibodies. Although the scFv-Fcs are clearly potent antiviral
agents, they are not complete human monoclonal antibodies.
Converting the scFv-Fcs to a full-length human IgG will po-
tentially increase their efficacy by allowing for more flexible
torsion around the hinge region.
All of the phage-selected antibodies produced in this study
mapped to DI/DII of the WNV E protein. The majority of
flavivirus antibodies characterized to date have been produced
in mice, and it is apparent from this and another recent study
(9) that human and other phage-displayed antibodies map to
new, uncharacterized E protein epitopes. Further work to fine
map these antibodies will help to further elucidate the regions
of DI/DII that define these important protective epitopes.
The scFv-Fcs characterized in this study were produced by
screening two antibody phage display libraries for molecules
that bound the WNV E protein. Because of the nature of the
creation of the libraries, these phage-displayed scFvs do not
necessarily represent the same antibodies that would be found
naturally occurring in an immunized or immune individual.
The phage libraries were created with random recombination
of VH and VL regions; therefore, the particular VH-VL com-
binations found in these antibodies are potentially entirely
unique. Additionally, creation of antibodies by phage display
eliminates the phenomenon of immunodominance of certain
epitopes because there is no major histocompatibility restric-
tion. Using a phage display screen is thus a way to identify
novel and potent high-affinity antibodies to a target of interest
in the absence of the constraints of the immune system.
The use of antibodies as a therapy for human flavivirus
infections is promising, especially for elderly and immunocom-
promised patients with a deficient immune response. A mono-
clonal molecule such as the ones identified in this study may be
an ideal therapy as it can be developed rapidly to a high titer,
is free of blood-borne pathogens, and is specifically targeted to
important protective epitopes. The in vivo protection and ther-
apy provided by these molecules suggest that these antibodies
can be further developed into a potent prophylaxis and therapy
for WNV and related flavivirus infections. Human clinical tri-
als are needed to establish a role for human monoclonal anti-
bodies in the treatment and prevention of flavivirus infections.
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